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Abstract 
Coarctation of the aorta (CoA) is a common congenital cardiovascular (CV) defect characterized by a stenosis of 
the descending thoracic aorta. Treatment exists, but many patients develop hypertension (HTN). Identifying the 
cause of HTN is challenging because of patient variability (e.g., age, follow-up duration, severity) and concurrent 
CV abnormalities. Our objective was to conduct RNA sequencing of aortic tissue from humans with CoA to 
identify a candidate gene for mechanistic studies of arterial dysfunction in a rabbit model of CoA devoid of the 
variability seen with humans. We present the first known evidence of natriuretic peptide receptor C (NPR-C; 
aka NPR3) downregulation in human aortic sections subjected to high blood pressure (BP) from CoA versus 
normal BP regions (validated to PCR). These changes in NPR-C, a gene associated with BP and proliferation, were 
replicated in the rabbit model of CoA. Artery segments from this model were used with human aortic 
endothelial cells to reveal the functional relevance of altered NPR-C activity. Results showed decreased 
intracellular calcium ([Ca2+]i) activity to C-type natriuretic peptide (CNP). Normal relaxation induced by CNP and 
atrial natriuretic peptide was impaired for aortic segments exposed to elevated BP from CoA. Inhibition of NPR-C 
(M372049) also impaired aortic relaxation and [Ca2+]i activity. Genotyping of NPR-Cvariants predicted to be 
damaging revealed that rs146301345 was enriched in our CoA patients, but sample size limited association with 
HTN. These results may ultimately be used to tailor treatment for CoA based on mechanical stimuli, genotyping, 
and/or changes in arterial function. 
INTRODUCTION 
Excessive mechanical forces such as blood pressure (BP), wall tension, and strain contribute to pathologic 
remodeling of the aorta and arterial system (22, 39), which can lead to substantial morbidity (24). Morbidity in 
the form of hypertension (HTN) is common in children with coarctation of the aorta (CoA), one of the most 
common congenital cardiovascular (CV) defects that is characterized by a constriction of the descending thoracic 
aorta. Currently there is treatment, but no cure for CoA. The cause of HTN in CoA patients remains unknown 
despite the first surgical treatment being conducted ~75 yr ago (18). Genetic factors are believed to be 
associated with CoA and may contribute to persistent morbidity after treatment (14, 33). However, the specific 
genes contributing to the pathology of CoA, and their functional relevance, remain unknown. 
Identifying the mechanisms of morbidity is difficult in humans with CoA due to confounding variables such as 
differences in age at repair, time between correction and follow-up, severity of CoA before correction, and 
concurrent anomalies (e.g., bicuspid aortic valves or septal defects). While there is likely a causal genetic basis 
for the initial presentation of CoA in humans, there are also likely changes in gene expression resulting from 
mechanical stimuli on the vasculature as a result of the CoA shortly after birth (9, 16). To address this 
complexity, we previously developed a rabbit model that allows us to study the mechanical consequences of 
CoA independently of the confounding variables mentioned above (26). This model replicates aortic changes in 
humans and mimics correction at various durations using dissolvable suture (Fig. 1). Our results to date using a 
putative clinical treatment guideline (20 mmHg BP gradient) with this model have revealed increased medial 
wall thickness and stiffening, a phenotypic shift in smooth muscle cells (SMC) to the dedifferentiated state, and 
endothelial dysfunction as evident by decreased nitric oxide (NO) relaxation (via acetylcholine stimulation), all of 
which persist after correction (25). Microarray analysis of aortic tissue from this model identified several 
differentially expressed genes (DEG) in the region exposed to pronounced mechanical stimuli developing from 
CoA (19). The objective of the current investigation was to use RNA sequencing (RNA-Seq) of aortic tissue from 
humans with CoA to identify one or more candidate genes for use in future mechanistic studies of coarctation 
induced arterial dysfunction. We then sought to determine the association of any candidate genes with the 
likelihood of HTN in a larger cohort of patients with CoA from our center. Specifically, we present the first known 
evidence of natriuretic peptide receptor C (NPR-C; also known as NPR3) downregulation in humans treated for 
CoA and use our rabbit model of CoA to show the functional relevance of coarctation induced changes in NPR-C. 
 
Fig. 1.Magnetic resonance images showing the similarity between untreated and treated coarctation of the 
aorta (CoA) in humans (left top) vs. a rabbit model (left bottom) developed to study mechanisms of arterial 
dysfunction in the absence of concurrent anomalies. Yellow arrows denote treatment sites. The right images 
show CoA suture (black arrows) and resulting blood pressure gradient (BPG) for groups of juvenile rabbits (n = 
7/group) with 20 mmHg BPG. Symbols indicate significantly (P < 0.05) different from Control (*) and Treated (§) 
groups. 
METHODS 
All procedures were reviewed and approved by the Institutional Review Board and Institutional Animal Care and 
Use Committee of the Children’s Hospital of Wisconsin, Medical College of Wisconsin, and Marquette University 
as previously described (26, 34). 
Human RNA sequencing and genotyping. 
Samples for the current study were extracted from the Congenital Heart Disease Tissue Bank at our institution 
for two purposes. Sections from above (proximal; high BP region) and below (distal; low BP region) the 
coarctation were extracted from patients for RNA-Seq and transcriptome analysis. White blood cell DNA from 
242 CoA patients was subsequently used for genotyping as described in more detail below. All tissue was 
obtained after consent and at the time of corrective surgery. 
Transcriptome isolation. 
RNA-Seq analysis of samples was performed similar to details described previously (35). Briefly, aortic tissue for 
RNA-Seq was selected from six CoA patients (average age = 6.5 yr, range 0.31–11 yr; Table 1) with an upper 
extremity systolic BP >99th percentile for their sex, height, and age according to the National High Blood 
Pressure Education Program (NHBPEP) Working Group on Children and Adolescents (27a), thereby focusing on 
mechanical consequences imposed by the coarctation. RNA was isolated from aortic samples (~10 mg) by 
enzymatic digestion with an Ambion MELT kit (Invitrogen), which includes an “on-bead” DNase digestion step to 
remove contaminating genomic DNA. Samples were homogenized with glass tissue grinders needed for fibrous 
samples. The Qiagen RNeasy Fibrous Minikit (Qiagen; Valencia, CA) was then used according to the 
manufacturer’s instructions. Isolated RNA was of high quality as determined by Bioanalyzer 2100 RNA integrity 
number (Table 1; Agilent Technologies). RNA sequencing libraries were prepared from 500 ng total RNA using 
the Illumina TruSeq kit (version 2.5). Samples were spiked with external RNA controls (ERCC sequences; Ambion 
Life Technologies, Grand Island, NY). Unique indexes were introduced according to the protocol in order for 
sample multiplexing during the sequencing run. Library quantitation was accomplished by quantitative (q)PCR, 
and subsequent sequencing was carried out on an Illumina HiSeq 2000 platform. Approximately 35 million 
paired-end reads were generated per sample. 
Table 1. Patient characteristics, sample locations, and RNA quality 
Subject Age, yr Sex Preop BP, 
systolic/diastolic 
Sample 
Location 
RNA Integrity 
# 
Matched Pair (yes 
= X) 
1 5.6 M 139/91 proximal 8.3 X 
    distal 8.2  
2 9.3 M 126/71 proximal 7.6 X 
    distal 8.7  
3 0.3 M 118/69 proximal 7.0 X 
    distal 8.2  
4 8.0 F 133/58 proximal 8.0 X 
    distal 8.1  
5 11 F 134/80 proximal 7.4  
6 5.2 M 130/89 distal 7.8  
Average (SD) 6.5 (3.7)   Average (SD) 7.9 (0.49)  
BP, blood pressure. 
Transcriptome data analysis. 
Illumina HiSeq 2000 paired-end reads were mapped to the human genome (NCBI b37) using gapped alignment 
software Bowtie (36) under RSEM 1.2.7. Quantification to posterior mean estimate transcripts per million (TPM) 
was performed by RSEM (http://deweylab.biostat.wisc.edu/rsem/) across a transcriptome reference of 38,642 
from RefSeq (genes, alternative transcripts, mitochondrial sequences, and spiked-in ERCC controls). Transcripts 
were analyzed with EdgeR by scaling TPM to produce pseudocounts, calculating normalization factors, then 
estimating GLM common, trended, and tagwise dispersions. EdgeR is a standard package of the R programming 
language for differential expression analysis. A likelihood ratio test evaluated each transcript’s model 
significance by tissue location (proximal vs. distal). The generalized linear modeling functionality in EdgeR was 
used to perform paired samples test (31). A P value < 0.05 was considered statistically significant, yielding DEG. 
Results were filtered to retain those transcripts with absolute log fold change and expression (logCPM) greater 
than one. EdgeR results were processed by removing DEG within the proximal vs. distal sections for any 
individual subject, thereby leaving only those DEG with significant changes in expression across all patients. 
DEG from the RNA-Seq analysis of aortic tissue from humans with CoA above were compared with those from a 
prior study generating DEG from proximal aortic tissue of untreated CoA, treated CoA, or control rabbits (19). 
Three common DEG emerged: DENN domain containing 2D (DENND2D), ArfGAP with coiled-coil, ankyrin repeat 
and PH domains 1 (ACAP1), and NPR-C. In contrast to DENND2D and ACAP1, a comprehensive literature search 
suggested a potential role for NPR-C in the vasculature (3, 5, 15, 21). NPR-C was therefore determined to be the 
most promising and pragmatic candidate for more detailed functional analysis in the rabbit model of CoA and 
cell culture approaches. The relative quantification of NPR-C vs. GAPDH was then compared between RNA-Seq 
results and qPCR (TaqMan Assay ID: Hs01099013_m1). 
Genotyping for NPR-C variants. 
At the time of study, there were five known single-nucleotide polymorphisms (SNPs) for NPR-C that are 
associated with high systolic BP or HTN (Table 2). We identified one additional NPR-C variant (Table 
2; rs146301345) from a population of ~200 patients whose tissue underwent whole exome or whole genome 
sequencing at our center previously (13, 35). These patients had hypoplastic left heart syndrome (HLHS), which 
is a congenital cardiovascular disease often including CoA (67–80%) (12). 
  
Table 2. SNPs associated with elevated BP and/or HTN 
Reference 
SNP 
MAF (1000 Genomes 
Project) 
C-
score 
Associated Phenotype Supporting 
Literature 
PMID TaqMan Assay ID 
rs1173756 t = 0.3740/1873 0.13 systolic BP Wain et al. 21909110 C 8809430_1_ 
rs1173766 t = 0.3988/1997 0.06 HTN; 1.16 odds ratio Kato et al. 21572416 C 27051776_10 
rs1173771 A = 0.3391/1698 -0.14 systolic BP Ehret et al. 21909110,21909115 C 8809478_10 
rs1421811 G = 0.2778/1391 0.06 systolic BP Johnson et al. 22100073 C 8809215_10 
rs2270915 G = 0.1955/979 1.90 systolic BP; 4 yr CV mortality 
12.5% 
Saulnier et al. 21464461 C 15958985_20 
rs146301345 A = 0.0008/4 2.55 height Marouli et al. 28146470 C_171467879_10 
CV, cardiovascular; HTN, hypertension; MAF, minor allele frequency; SNP, single nucleotide polymorphism. 
  
Several scoring algorithms (2, 28, 30) were employed to assess functional damage of variants and calculate a C-
score (17). Analysis of rs2270915 within the group of HLHS patients from our center mentioned above (some of 
which also have CoA) revealed a frequency of ~65%, as compared with 14–22% in U.S. populations without CoA. 
Interestingly, rs146301345 was present in two of these patients studied. These two SNPs are likely to 
render NPR-C nonfunctional, with scoring values indicating they are highly intolerant and damaging 
(e.g.; rs2270915 C-score = 1.90 and rs146301345 C-score = 2.55). Detection of these two NPR-C variants was 
therefore performed using TaqMan Predesigned SNP Genotyping Assays and buffy coat DNA from 242 total CoA 
patient samples obtained at the time of corrective surgery. Primers and probes were purchased from Applied 
Biosystems (Foster City, CA), and probes were labeled with the fluorescent dyes VIC and FAM. Assays were 
performed using TaqMan Universal Master Mix, with 20 ng of DNA per reaction. The reaction was carried out 
with a total reaction volume of 5 μl, following an amplification protocol suggested by the manufacturer, with 30 
DNA samples run per plate. Genotype was called using the QuantStudio 7 Flex Real-Time PCR System in the 
presence of a known positive control for each genotype and a no template negative control. Allele and genotype 
frequencies of NPR-C were obtained by direct counting. Comparison of variant frequencies in our CoA patients 
to the global population was done using the minor allele frequency (MAF) calculation. The global population 
information was found on NCBI’s SNP database (dbSNP) 1000 Genomes project. 
Relating NPR-C variants to HTN in CoA patients. 
Clinical records were retrospectively analyzed to relate NPR-C variants to HTN status using age, sex, height, and 
follow-up BP. Patients <18 yr at follow-up were evaluated using the NHBPEP Working Group on Children and 
Adolescents (27a) criteria for systolic and diastolic BP: normal (≤50th percentile BP), pre-HTN (≥50th but <99th 
percentile BP), HTN (≥99th percentile BP). Patients ≥18 yr at follow-up were evaluated using Joint National 
Committee seven guidelines for BP: normal (<120/80 mmHg), pre-HTN (120–139/80–89 mmHg), HTN 
(includes stage 1: 140–159/90–99 mmHg and stage 2: >160/>100 mmHg). An error-correcting output code for 
multiclass learning (i.e., machine learning) in MATLAB was proposed with a range of classifiers (e.g., Logistic 
Regression, Support Vector Machines, Ensemble, etc.) and predictors (e.g., the patient covariates such as age 
and sex) to determine if either variant alone, in concert with each other and other covariates, is sufficiently 
predictive of HTN status to be applied with future CoA patients. 
Assessing functional significance using cell culture and intact arteries. 
Cell culture and ex vivo intact artery approaches were used to assess the potential functional relevance of 
changes in NPR-C using associated agonists and inhibitors. Human aortic endothelial cells (HAEC) from Cell 
Biologics (Chicago, IL) were cultured with the manufacturer’s recommended media. HAEC were split in a 1:3 
ratio every 3–4 days after initial plating from a frozen vial into a T25 cell culture flask. The cells were transferred 
to six-well plates at passage 8 and left to grow for 4–5 days to reach confluence. HAEC (n = 4/group) intracellular 
calcium transients ([Ca2+]i) were recorded during experimentation with a confocal imaging system Leica TCS 
MP5. Imaging settings were chosen to allow for continuous image capture every 2.3 s and set for a maximum 
duration of 5 min. After starting acquisition, C-type natriuretic peptide [CNP; induces relaxation via NPR-C (4, 7)] 
or cANF4–23 (specific NPR-C agonist) was diluted into the dish to concentrations of 1.5e-6M and 7.5e-7M, 
respectively. These doses balanced response to an agent with cellular toxicity. The experiment ended, and the 
image stack was saved when no additional changes in intensity were observed for 20 s. 
Images were quantified using the Loci Tools plugin within ImageJ (National Institute of Health). Briefly, image 
frames corresponding to times just before drug administration, and the peak response time (for dimming or 
elimination) were determined. The Measurement option within the Analyze tool was then employed using at 
least four cells at each time point. Resulting intensities were normalized to background. The EC response to CNP 
and cANF4–23 was also quantified after pretreatment with the NPR-C specific inhibitor, M372049, (AstraZeneca) 
(37) for 45 min. Experiments were repeated using four separate plates for each group. Normalized intensities 
were then averaged, and statistical analysis was performed as described in the myography methods below. 
To confirm the HAEC experiments above replicate the in vivo condition, we assessed the endothelial response to 
CNP under normal deformation and pathologic conditions from CoA with intact aortic sections from the 
transverse arch of rabbits (n = 5) exposed to CoA induced by wire of known diameter (0.051–0.064”). Data from 
control rabbits (n = 3) were also obtained. Specifically, two-photon microscopy was used to visualize and 
quantify [Ca2+]i mobilization in response to CNP for endothelial cells from proximal and distal aortic sections of 
Control and CoA rabbits exposed to CoA by methods described in detail elsewhere (10, 11, 29). Briefly, aortic 
segments were extracted, opened longitudinally, and loaded with the Ca2+ dye, Fluo-4AM (5 μM, Life 
Technologies), using 0.05% pluronic acid (Pluronic F-127, Sigma-Aldrich) in physiological salt solution (PSS) for 1 
h. Aortas were washed and then transferred to a silicone-coated plate containing 2 mM Ca2+ buffer, where they 
were pinned down with the endothelium facing upright. The plate was then transferred to an upright Olympus 
Fluoview FV1000 microscope (Olympus) equipped with Ti:sapphire lasers tuned to 820 nm and imaged with a 
25X (N.A. 1.05 and working distance 2 mm) water-immersion objective lens (XLPL25XWMP, Olympus). The 
fluorescent response was imaged within EC after addition of 10 µM CNP. Images were taken every 1.6 s. Average 
Ca2+ transients of EC were calculated for proximal and distal sections (n ≥ 9 cells per location). One rabbit of each 
group was used to optimize incubation and signal intensity protocols for use with two-photon imaging. Two 
samples from each vascular region (i.e., proximal and distal) were studied for each rabbit. 
The arterial response to potential changes in NPR-C was measured by myography (26). Relaxation was measured 
for endothelium-intact arterial rings from proximal and distal locations (n = 2/location) of the same CoA and 
Control rabbits used for two-photon microscopy. Relaxation via NPR-C was studied in cumulative doses (10−9 to 
10−6 M) of CNP and atrial natriuretic peptide (ANP), which is also reported to have a strong affinity for NPR-C 
(23). Aortic segments from the descending thoracic aorta upstream of the coarctation (i.e., proximal) and just 
downstream of any poststenotic dilatation (i.e., distal) were precontracted with 0.32 μM phenylephrine (PE) 
before each dose response, and relaxation curves were constructed as percentages of precontracted tension. 
Care was taken to ensure and present data only from samples with a similar level of tension at the start of each 
cumulative dose response. Samples were rinsed with fresh PSS three times and allowed to relax back to resting 
tension after the conclusion of each dose response. In separate trials, arteries were incubated with 10 μM of the 
NPR-C specific inhibitor (37) M372049 for 30 min. Additional CNP and ANP cumulative dose responses were then 
conducted in the presence of the inhibitor. Statistical analysis was conducted by one-way multiple analysis of 
variance (ANOVA). A P value <0.05 was considered statistically significant. 
RESULTS 
Transcriptome analysis. 
RNA-Seq of aortic tissue harvested during surgical treatment of human CoA patients revealed a statistically 
significant reduction in the normalized expression of NPR-C for proximal as compared with distal sections (Fig. 
2A). Relative quantification of NPR-C vs. GAPDH from these samples showed a good correlation (R-value of 0.8) 
with those from qPCR. Rabbit aortic tissue from the proximal region exposed to elevated BP due to the presence 
of a 20 mmHg coarctation (19) caused a decrease in NPR-C intensity in untreated as compared with control 
rabbits, and this decrease persisted in proximal aortic tissue of rabbits whose coarctation had been relieved by 
resorption of the dissolvable Vicryl suture used to create the initial constriction. 
 
Fig. 2.Normalized natriuretic peptide receptor C (NPR-C) expression from RNA sequencing (RNA-Seq) of aortic 
tissue harvested during surgical treatment of human CoA patients (A). All patients had systolic blood pressure 
(BP) >99% for age, thus underscoring the mechanical impact of CoA. Prior microarray results from a rabbit model 
of CoA (B) also showed a decrease in NPR-C transcript levels in proximal aorta exposed to elevated BP from the 
presence of a coarctation. Data expressed as means ± SE. *P < 0.05. 
Cell culture and intact artery experiments. 
HAEC showed rapid decrease in cytosolic [Ca2+]i response (Fluo-4 AM) in response to 1.5e-6M CNP relative to the 
baseline period before CNP administration. The NPR-C agonist cANF4–23 increased [Ca2+]i level at a dose of 7.5e-
7M. Both responses were blocked by the NPR-C inhibitor M372049 (Fig. 3) when evaluated at the same 
respective time durations following respective substance administration. 
 
Fig. 3.Human aortic endothelial cells (HAEC) showed decreased intracellular calcium ([Ca2+]i) response to C-type 
natriuretic peptide (CNP, 1.5e-6M). The NPR-C agonist cANF4–23 (7.5e-7M) increased [Ca2+]i release. Both 
responses were blocked by the NPR-C inhibitor M372049. *P < 0.05 vs. Baseline. 
The average catheter-based BP gradient measured in CoA rabbits of the current study was 17 mmHg, while that 
measured from spatially equivalent locations of Control rabbits was 1 mmHg. Similar to HAEC, two-photon 
imaging of EC within intact aortic segments from proximal and distal locations of Control rabbits revealed a 
decrease in [Ca2+]i in response to CNP (Fig. 4). This decrease in was also observed for intact aortic segments from 
the distal aorta of CoA rabbits where there was normal BP in vivo. In contrast, for CoA rabbits the 
[Ca2+]i response to CNP from proximal aorta segments experiencing high BP in vivo was significantly attenuated 
when compared with the distal segments (Fig. 4). 
 
Fig. 4.Two-photon images of [Ca2+]i levels from endothelial cells (EC) within intact sections for groups of Control 
and CoA rabbits at baseline and upon administering CNP (10 μM). Temporal results show differences in proximal 
vs. distal locations (n = 9 EC/location). CNP decreased [Ca2+]i response for ECs within both sections of Control 
rabbits and distal sections of CoA rabbits, but this response is absent in proximal sections of CoA rabbit, which 
were exposed to high BP in vivo. 
Figure 5 shows active relaxation of the aorta to CNP and ANP from CoA and Control rabbits. There were no 
differences in relaxation of proximal vs. distal aortic rings from Control rabbits when exposed to increasing doses 
of CNP or ANP (Fig. 5, top row). In contrast, there was a statistically significant attenuation of relaxation in 
proximal as compared with distal aortic rings for CoA rabbits when exposed to all doses of CNP and ANP (Fig. 
5, middle row). ANP-induced relaxation of aortic rings from proximal and distal locations was nearly twice that 
observed with CNP. Dose-dependent relaxation to CNP and ANP was impaired and not statistically different 
between proximal and distal aortic rings following pretreatment with the NPR-C inhibitor M372049 (Fig. 
5, bottom row). 
 
Fig. 5.Dose-dependent relaxation of the proximal and distal aorta to CNP (left) and atrial natriuretic peptide 
(ANP, right) for groups of Control and CoA rabbits. Relaxation of proximal and distal aortic rings was not 
different in samples from Control rabbits (top row). There was statistically significant attenuation of relaxation in 
proximal as compared with distal aortic rings for CoA rabbits when exposed to all doses of CNP and ANP 
(middle row). Residual relaxation to these peptides was abolished by pretreatment with the NPR-C inhibitor 
M372049 (bottom row). PE, phenylephrine. 
Genotyping of NPR-C variants. 
DNA samples of patients from our center were genotyped to determine if HTN in CoA patients may be 
associated with the NPR-C variants rs2270915 and rs146301345, which are predicted to be highly intolerant and 
damaging. Figure 6 shows allelic discrimination plots from samples on representative plates for each variant. 
Figure 6, left, reveals the majority of CoA patients have an rs2270915 genotype of AA, while AG is also common. 
We therefore focused on samples from CoA patients that were homozygous for the opposite allele (GG; within 
the ellipse). Figure 6, right, shows samples for rs146301345 that are homozygous for the VIC probe, which 
corresponds to a genotype of GG. This is the common genotype in the human population, therefore focusing our 
interest to samples that were heterozygous, as shown by those within the ellipse. The frequencies of NPR-
C variant genotypes in our CoA cohort from all plates are summarized in Table 3. 
 
Fig. 6.Allelic discrimination plots for a representative plate from each NPR-C variant. Samples with the 
noncommon genotype for each variant are indicated by the ellipses. 
Table 3. Frequency of NPR-C variant genotypes in the current cohort of CoA patients 
 Genotype Patients, n Percentage 
rs2270915 A/A 155 64.1 
 G/A 71 29.3 
 G/A 16 6.61 
46301345 A/A 0 0 
 A/G 5 2.07 
 G/G 237 97.9 
 
For rs2270915, the minor allele is G, which has a frequency of 19.6% in the global population, having been 
observed 979 times in the sample population of 2,500 people (or 5,000 chromosomes). Similarly, our current 
cohort of CoA patients revealed a frequency for rs2270915 of 21.3%. The minor allele for rs2270915 was 
detected 103 times in 242 patient samples (484 chromosomes). The minor allele for rs146301345 is A. This 
variant is more rare in the global population with a frequency of only 0.08% (4 of 2,500 people, or 5,000 
chromosomes). In contrast, rs146301345 was significantly enriched in our cohort of CoA patients having been 
observed five times in just 242 people (or 484 chromosomes). 
Unfortunately, rs2270915 and rs146301345 alone, or together, did not have sufficient predictability to 
determine HTN status in our cohort. Calculation of sample size using the descriptive statistics above for these 
variants in our CoA cohort indicates ~2,500 patients must be studied to determine the ability of rs146301345 to 
predict hypertensive status. 
DISCUSSION 
For unknown reasons, treated CoA patients often have a reduced life expectancy from CV morbidity, primarily 
from HTN (8). Upon closer review, there are several potential contributors to arterial pathology in CoA. 
Putatively, there is a causal genetic basis for the initial narrowing. The prevailing causal hypothesis is based on 
histology showing that tissue with features similar to the ductus arteriosus (DA) also exists near the coarctation, 
suggesting CoA may be created during closure of the DA in the first week of life (9, 16). Closure of the DA leads 
to the secondary consequence of exposing the aortic arch and arteries above the coarctation to mechanical 
stimuli including elevated BP and a gradient across the narrowing. Treatment approaches that mitigate the 
secondary consequence of CoA may ultimately reduce morbidity for a large number of CoA patients and 
individuals with refractory HTN attributable to prolonged mechanical stimuli. 
The critical barriers to identifying the mechanisms of morbidity in humans with CoA from causal or mechanical 
sources include a relatively small number of heterogeneous patients at each center. To circumvent these 
barriers the current investigation analyzed gene expression data from an animal model of CoA largely devoid of 
the heterogeneity seen clinically (26) based on RNA-Seq results of human aortic tissue harvested during surgical 
treatment. The goal of this approach was to identify a candidate gene that could be further studied in the rabbit, 
but that was motivated from humans with CoA who had upper extremity systolic BP >99th percentile for their 
sex, height, and age, thereby focusing on mechanical consequences. The primary finding of the current 
investigation is that RNA-Seq from humans treated for CoA revealed downregulation of NPR-C in proximal 
sections of the thoracic aorta subjected to high BP when compared with sections from regions in the distal 
thoracic aorta exposed to normal BP. Importantly, microarray data from our experimental rabbit model of CoA 
also showed downregulation of NPR-C in proximal aortas from both CoA and treated rabbits experiencing high 
BP, as compared with controls experiencing normal BP (Fig. 2). 
NPR-C is a single transmembrane receptor coupled to the activation of phospholipase C beta-3 (27) through 
beta-gamma subunits and adenylyl cyclase inhibition via inhibitory guanine nucleotide regulatory protein (Gi) 
(3). NPR-C is found in many tissues including SMC where it has been shown to play a role inhibiting proliferation 
(5, 15), and endothelial cells where recent literature suggests a role in re-endothelialization and viability under 
healthy conditions (15). Prior studies also point to a role in regulating BP (3) as systemic administration of an 
NPR-C agonist attenuated high BP in spontaneously hypertensive rats by inhibiting enhanced levels of Gi (21). 
NPR-C is one of three receptors for natriuretic peptides that include ANP, brain (BNP) and CNP. ANP and BNP are 
mostly found in the atria and ventricles, whereas CNP is abundantly expressed in vascular EC (4, 7). Activation of 
NPR-C increases eNOS activity resulting in the formation of NO and vasorelaxation via cGMP. While this prior 
literature implicates NPR-C in arterial dysfunction, the current investigation is the first to show altered NPR-
C transcript levels in aortic tissue from human CoA patients. 
Similarity in trends between the current human RNA-Seq results and prior microarray results from rabbits with 
CoA suggest that the rabbit provides a unique model to further unravel the contribution of NPR-C to CoA-
induced arterial dysfunction. Indeed, the data in Figs. 4 and 5 show the functional relevance of NPR-C 
impairment in the vasculature using this model and are consistent with the cell culture results in Fig. 3. 
Collectively these data provide the first exciting evidence of a functional relevance for changes in NPR-C from 
CoA. 
The current results show promising evidence of functional ramifications to altered NPR-C activity from 
pronounced mechanical stimuli. Interestingly, genome-wide association studies (GWAS) have uncovered several 
known SNPs for NPR-C that are associated with high systolic BP or HTN (Table 2). For 
example, rs2270915 presents in 14–22% of U.S. populations (1000 Genomes Project), with the altered genotype 
having higher systolic BP and sodium response (32). While our rabbit model of surgical coarctation induction 
certainly suggests decreased NPR-C transcript levels are a secondary consequence of mechanical stimuli, aortic 
tissue from humans with CoA that was used for RNA-Seq may theoretically include changes in gene expression 
from causal as well as mechanical sources. We attempted to mitigate this issue by using tissue from patients 
who had upper extremity systolic BP >99th percentile for their sex, height, and age, thereby focusing on the 
mechanical consequences of the coarctation. Nevertheless, an alternative hypothesis is that normotensive CoA 
patients may simply have a normal NPR-C genotype. The ability to genotype CoA patients for NPR-C variants is 
attractive as a potential screening tool, as it could explain the presence of HTN even in CoA patients who have 
undergone optimal treatment with no residual blood pressure gradient. While the MAF for rs2270915 in the 
current CoA cohort was not different from the general population, the more rare SNP, rs146301345, was 
enriched in our cohort of coarctation patients. This finding suggests that in addition to mediating coarctation-
induced arterial dysfunction from mechanical stimuli, NPR-C may in some way be causal for HTN in CoA. The full 
understanding of this finding is not currently known and may elude researchers for some time as our sample size 
estimates from power analyses indicate ~2,500 CoA patients will be needed to statistically determine 
whether rs146301345 is associated with HTN. This represents a large number as most centers will see ~20 new 
CoA patients annually. Moreover, updated guidelines for the prevention, detection, evaluation, and 
management of BP were recent released, which includes BP categories that differ slightly from those used in the 
current study (38). Future studies using the updated guideline and categories will be needed to determine 
potential association with HTN. Additional studies will also be needed to better understand the precise 
mechanism(s) by which NPR-C variants seen clinically result in HTN via markers of endothelial function (e.g., NO 
release). 
The current results should be interpreted relative to several potential limitations. Healthy aortic tissue was not 
available from an age- and sex-matched cohort of subjects. We therefore used distal aortic tissue we know to be 
exposed to a normal range of BP (20, 25), even though other mechanical stimuli such as wall shear stress may 
impact gene expression downstream of the coarctation. We acknowledge that different approaches were used 
to quantify changes in gene expression between humans and rabbits exposed to CoA. This was unfortunate but 
is an unavoidable consequence resulting from the continuing evolution of genomic tools. To mitigate 
differences, DEG from completion of the data analysis process applied for each respective approach (RNA-Seq 
vs. microarray) were compared with identified candidate genes. Moreover, the data featured here in support of 
a functional role for altered NPR-C activity, and that rs146301345 seems to be enriched in our coarctation 
patients, suggest that NPR-C is indeed a target of relevance to CoA. In contrast to finding new rare SNPs, we 
focused on SNPs known to be associated with high BP given the prevalence of HTN in CoA (32.5%, range 25–
68%) (6). Moreover, uncovering new variants from the population of CoA patients at one center is difficult due 
to a limited sample size. Two-photon imaging is best performed on fresh tissue sections, and the extended 
duration of associated imaging sessions following tissue harvest precluded the additional study of responses to 
ANP via two-photon imaging as was performed via myography. 
In conclusion, the current investigation identified NPR-C as a potential contributor to arterial dysfunction in CoA 
patients for the first time. Specifically, RNA-Seq of tissue from humans with CoA showed downregulation 
of NPR-C in proximal aortic sections exposed to elevated BP, as compared with distal sections from 
normotensive regions. Complementary microarray data from an experimental rabbit model of CoA similarly 
showed downregulation of NPR-C in proximal aortas from both CoA and treated rabbits experiencing high BP as 
compared with control rabbits experiencing normal BP. Intact artery segments from this experimental model 
were used with HAEC to obtain data on the functional ramifications of altered NPR-C activity. Both approaches 
showed decreased [Ca2+]i activity in response to CNP administration under normal conditions. The normal 
response to CNP and ANP is abolished for aortic segments previously exposed to elevated BP from CoA. 
Moreover, NPR-C could represent a potential therapeutic target as pharmacological inhibition resulted in 
impaired aortic relaxation. Of the known NPR-Cvariants predicted to be highly intolerant and 
damaging, rs146301345 was found to be enriched in our cohort of CoA patients, but a small samples size 
precluded determination of its potential association with HTN in CoA patients. These results may ultimately be 
used to suggest a new paradigm for CoA treatment based on mechanical stimuli, genotyping, and/or changes in 
arterial function assessed clinically after confirmation of the current important findings in larger studies. 
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